Fluorouracil (5-FU) is an essential component of systemic chemotherapy for colorectal
cancer (CRC) in the palliative and adjuvant settings. Over the past four decades, several …

Colorectal cancer (CRC) is often diagnosed at an advanced stage when tumor cell
dissemination has taken place. Chemo-and targeted therapies provide only a limited …

The most recent version of the European Society for Medical Oncology (ESMO) consensus
guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was …

Immunotherapy has revolutionized colon cancer treatment. Immune checkpoint inhibitors
(ICIs) have shown clinical benefits for colon cancer patients, especially those with high …

One of the primary mechanisms of tumor cell immune evasion is the loss of antigenicity,
which arises due to lack of immunogenic tumor antigens as well as dysregulation of the …

The association between mutations of key driver genes and colorectal cancer (CRC)
metastasis has been investigated by many studies. However, the results of these studies …

Microsatellite instability‐high (MSI‐H) is an important biomarker for predicting the effect of
immune checkpoint inhibitors (ICIs) on advanced solid tumors. Microsatellite instability‐high …

An increasing number of studies have shown that immunotherapy serves a significant role in
treating colorectal cancer (CRC) and has become a hotspot. However, few studies used the …

The peritoneum is a common site of dissemination for colorrectal cancer, with a poorer
prognosis than other sites of metastases. In the last two decades, it has been considered as …

Methods A search algorithm (Figure 1) based on a combination of the terms ''metastatic
colorectal cancer''AND “therapy” OR “treatment” AND “RAS” OR “KRAS” OR “NRAS” AND …